Home › Multiple Myeloma › Illinois › Bloomington
Multiple Myeloma clinical trials in Bloomington, IL
3 studies for Multiple Myeloma are looking for participants at sites in and around Bloomington (within about 30 miles). Open a study to see who can join and how to contact the study team.
Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse
RecruitingPhase 2
- Illinois CancerCare-Bloomington, Bloomington
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
RecruitingPhase 3
- Illinois CancerCare-Bloomington, Bloomington
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
RecruitingPhase 3
- Saint Joseph Medical Center, Bloomington
- Illinois CancerCare-Bloomington, Bloomington
About Multiple Myeloma
Multiple myeloma is a cancer that begins in plasma cells, a type of white blood cell. Discover symptoms, diagnostic tests, and treatments for myeloma.
More about Multiple Myeloma on MedlinePlus
Multiple Myeloma trials in other cities
- New York City, NY60 studies
- Boston, MA42 studies
- Atlanta, GA41 studies
- Houston, TX38 studies
- Durham, NC37 studies
- Nashville, TN32 studies
- Denver, CO26 studies
- Columbus, OH24 studies
- Baldwin Park, CA23 studies
- St. Louis, MO23 studies
- Rochester, MN23 studies
- Washington, DC22 studies
Other studies in Bloomington
- Non-Small Cell Lung Cancer11 studies
- Lung Cancer9 studies
- Colorectal Cancer7 studies
- Prostate Cancer7 studies
- Head and Neck Squamous Cell Carcinoma6 studies
- Breast Cancer5 studies
- Melanoma5 studies
- Hypopharyngeal Cancer5 studies
- Laryngeal Cancer5 studies
- Oral Cancer5 studies
- Pancreatic Cancer5 studies
- Endometrial Cancer4 studies
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.